BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12431818)

  • 1. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenesis: a possible treatment option for prostate cancer?
    Longoria RL; Cox MC; Figg WD
    Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic activity of prostate-specific antigen.
    Fortier AH; Nelson BJ; Grella DK; Holaday JW
    J Natl Cancer Inst; 1999 Oct; 91(19):1635-40. PubMed ID: 10511590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
    Schweizer MT; Carducci MA
    Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new drugs in angiogenesis.
    Ziche M; Donnini S; Morbidelli L
    Curr Drug Targets; 2004 Jul; 5(5):485-93. PubMed ID: 15216914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis of prostate cancer and antiangiogenic therapy.
    Uehara H
    J Med Invest; 2003 Aug; 50(3-4):146-53. PubMed ID: 13678383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis and prostate cancer: important laboratory and clinical findings.
    Cox MC; Permenter M; Figg WD
    Curr Oncol Rep; 2005 May; 7(3):215-9. PubMed ID: 15847713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis and prostate cancer tumor growth.
    Nicholson B; Theodorescu D
    J Cell Biochem; 2004 Jan; 91(1):125-50. PubMed ID: 14689586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenic drugs probable complement in cancer therapy].
    Christofferson R; Claesson-Welsh L; Muhr C
    Lakartidningen; 2002 Oct; 99(42):4138-9, 4142-8. PubMed ID: 12448292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.